Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Systematic Literature Review on the Burden of Disease for Patients With Moderate to Severe Acute Ischemic Stroke.
Medicine (Baltimore)
January 2025
Professor and SA Vice-Chair of Neurology at the University of California, Los Angeles, CA.
Background: A vast amount of literature is available on the burden of acute ischemic stroke (AIS). Yet, most information on AIS burden does not stratify by stroke severity, and the inclusion of mild strokes (National Institute of Health Stroke Scale < 5) might obscure the true impact of moderate-to-severe AIS. Therefore, it is important to understand the literature as it pertains to the epidemiological, clinical, humanistic, and economic burden of moderate-to-severe AIS from a global perspective.
View Article and Find Full Text PDFSmart approaches for encouraging the blood donation.
Asian J Transfus Sci
September 2022
Department of Pharmaceutics, School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Dehradun, Uttarakhand, India.
Blood is a life saver in many emergencies like accidents or for the patients suffering from deadly diseases such as cancer and thalassemia. Conventionally, blood collection is done in five steps, i.e.
View Article and Find Full Text PDFMagnitude of effect of low dose colchicine, a newly food and drug administration approved treatment for stroke prevention.
J Stroke Cerebrovasc Dis
February 2025
Comprehensive Stroke Center and Department of Neurology, Ronald Reagan - UCLA Medical Center, Los Angeles, CA USA. Electronic address:
Background: As the Food and Drug Administration in June 2023 approved low dose colchicine for primary prevention of stroke and other cardiovascular events, an updated meta-analysis of stroke outcomes in randomized trials would help inform clinical practice.**** METHODS: Systematic, study-level meta-analysis of randomized clinical trials of long-term colchicine in patients with established atherosclerotic cardiovascular disease (ASCVD, preponderantly primary prevention for stroke) or following non-cardioembolic ischemic stroke/transient ischemic attack (secondary prevention). Heterogeneity was assessed with the I statistic and Cochrane's Q and potential bias assessed with the Risk of Bias 2.
View Article and Find Full Text PDFAssociation Between Time to Treatment and Outcomes of Endovascular Therapy vs Medical Management in Patients With Large Ischemic Stroke.
Neurology
January 2025
From the Department of Emergency (G.Y., Lei Liu, H.X., J.W., C.L., J.X., F.H., B.H., D.W., H.W., C.F., Y.L., X.Z., W.Y., Z.H., Y.X., Libo Lei), Xiangtan Central Hospital (The Affiliated Hospital of Hunan University); Department of Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, China; Department of Neurology and Radiology (T.N.N.), Boston Medical Center, MA; Cerebrovascular Disease Department (X.H.), Beijing Anzhen Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (X.H., Y.P., M.W., Z.M.), Beijing; Interventional Neuroradiology (Y.P., M.W., Z.M.), Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (Z.Q.), The 903rd Hospital of the People's Liberation Army, Hangzhou, China; Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, CA; and Department of Neurology (X.C.), the Central Hospital of Lishui, the Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, Zhejiang, China.
Background And Objectives: Randomized trials have proven the benefit of endovascular therapy (EVT) for acute large ischemic stroke. This study was to characterize the effect of time to treatment on benefit of EVT vs medical management (MM) among patients with large ischemic stroke.
Methods: This was a post hoc analysis of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core randomized trial.
Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.
Lancet Neurol
December 2024
Department of Neurology and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. Electronic address:
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!